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Abstract
Approximately 1 million people in the United States and over 30 million worldwide are living
with human immunodeficiency virus type 1 (HIV-1). While mortality from untreated infection
approaches 100%, survival improves markedly with use of contemporary antiretroviral therapies
(ART). In the United States, 25 drugs are approved for treating HIV-1, and increasing numbers are
available in resource-limited countries. Safe and effective ART is a cornerstone in the global
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struggle against the acquired immunodeficiency syndrome. Variable responses to ART are due at
least in part to human genetic variants that affect drug metabolism, drug disposition, and off-site
drug targets. Defining effects of human genetic variants on HIV treatment toxicity, efficacy, and
pharmacokinetics has far-reaching implications. In 2010, the National Institute of Allergy and
Infectious Diseases sponsored a workshop entitled, Pharmacogenomics – A Path Towards
Personalized HIV Care. This article summarizes workshop objectives, presentations, discussions,
and recommendations derived from this meeting.
Keywords
HIV therapy; pharmacogenetics; pharmacogenomics; workshop
Access to antiretroviral therapy (ART) is a cornerstone in the fight against AIDS.1
Interindividual variability in ART pharmacokinetics, efficacy, and toxicity may be affected
by genetic variants relevant to drug metabolism, disposition, and off-site targets.2 In June
2010, the National Institute of Allergy and Infectious Diseases (NIAID) sponsored a
workshop entitled, Pharmacogenomics – A Path Towards Personalized HIV Care. The
impetus was the conviction that knowledge of associations between human genetics and
HIV treatment responses can benefit individuals and populations worldwide. This document
summarizes the workshop and resultant recommendations.
The workshop assembled individuals with complementary expertise to exchange ideas
relevant to HIV pharmacogenomics and to develop recommendations for advancing the
field. The first day included presentations by invited speakers, with intervening panel
discussions. Participants were then assigned to working groups – Accelerating
Pharmacogenomic Research, The Path from Bench to Beside, and Pharmacogenomics and
Clinical Trials – and were charged with drafting recommendations. Participants reconvened
on the second day to review recommendations.
HUMAN GENETIC PREDICTORS IN HIV TREATMENT
Current HIV pharmacogenomic knowledge was reviewed by David Haas. Orally
administered antiretrovirals undergo absorption, distribution, metabolism, and elimination
(ADME), and many ADME genes have functional variants. Non-ADME genes can also
affect treatment responses. Table 1 lists well-established associations between genetics and
antiretrovirals. Regarding HLA-B*5701 screening for abacavir hypersensitivity,3–6
guidelines recommend that test positivity be documented as abacavir allergy in the medical
record,7 but even such a beneficial test took many years to reach practice. Regarding the
relevance of CYP2B6 variants for efavirenz,8–13 population differences in genotype
frequency largely explain higher plasma efavirenz exposure among populations of African
ancestry. This together with an association between CYP2B6 and central nervous system
(CNS) adverse experiences8 led some clinicians to incorrectly infer that efavirenz should be
avoided in individuals of African descent. This highlights the potential harm resulting from
the uninformed use of genetic information. Multiple genetic variants are also associated with
nevirapine toxicities.14–17
Regarding strategies to find new associations, Amalio Telenti considered 3 aspects of
pharmacogenomic discovery: (1) intermediate versus clinical phenotypes; (2) genetic and
genomic approaches; and (3) discovery, replication, and functional validation. There are
many functional variants of potential importance in ADME genes, but for most
antiretrovirals little is known about effects of genetic variants on toxicity, efficacy, and
pharmacokinetics. To demonstrate that phenotypes with outliers are good endpoints, he
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described the skewed population distribution of lopinavir pharmacokinetics and the
discovery of a possibly causative variant in SLCO1B1.18,19 Multiple loss-of-function
variants along an ADME pathway may more profoundly affect pharmacokinetics.20
Genomic discoveries in the general population should be translated into the HIV field,
including markers of metabolic complications.21,22
Regarding issues in validation, Marylyn Ritchie discussed statistical issues in genomic
association studies. Without very large studies, genome-wide association studies (GWAS)
may miss true associations when using thresholds derived from Bonferroni correction (eg, P
< 5×10−8 for genome-wide significance), but accruing sufficiently large studies is not
always feasible. Alternatives include the false discovery rate, permutation testing, and
relaxed P-value thresholds, emphasizing effect sizes and independent replication. It is
unclear whether replication should be at the level of genes, gene pathways, or gene
networks. She introduced issues regarding allelic heterogeneity and population differences
and noted that most tagging single nucleotide polymorphisms (SNPs) are not functional.
Phenotypes may reflect combined effects of multiple rare variants in different individuals or
interactions among common and/or rare variants in the same individual. The importance of
phenotyping precision may depend on sample size and other aspects of study design.
TRANSLATING GENETIC TESTING INTO CLINICAL CARE
Regarding viral genetics and nongenetic factors, Daniel Kuritzkes reviewed the use of
laboratory assays for CD4 cells, HIV-1 RNA, viral drug resistance, and chemokine receptor
tropism to inform HIV treatment decisions. Factors associated with HIV disease progression
in untreated patients include HLA type, CCR5 genotype, and coinfections. Genomics
research has enhanced understanding of viral-host interactions. Host genetic markers could
potentially be used to stratify populations based on risk of disease progression, informing
decisions about when to start therapy. He considered host and viral factors that affect ART
response and noted the potential for genetics to elucidate underlying mechanisms of virus-
host interactions during ART.
The US Food and Drug Administration’s (FDA) role in bringing genetic tests to clinical
practice was discussed by Shashi Amur. Several FDA centers govern different aspects of
antiretroviral drugs and monitoring: Center for Drug Evaluation and Research (CDER) is
involved through drug approval and labeling; Center for Biologics Evaluation and Research
(CBER) approves tests for HIV monitoring; and Center for Devices and Radiological Health
(CDRH) approves human genetic tests. Genetic test information may be included in initial
labeling or added later, with strength of evidence affecting strength of label wording. She
emphasized an FDA goal of supporting development of genetic predictors of treatment
response and toxicity. The already successful incorporation of some genetic tests into
clinical care raises optimism that challenges can be overcome.
Lessons from warfarin studies were recounted by Brian Gage, including the initial
implication of multiple genes and a Web-based resource for pharmacogenetic dosing. Initial
studies identified an association between CYP2C9*2, *3 and warfarin metabolism, which
spurred trials of CYP2C9 genotype-based dosing. Initial studies were not highly successful,
in part due to reliance on a single gene. Subsequent collaborations demonstrated that to
accurately estimate warfarin dose, dosing equations should include at least 2 genes
(VKORC1 and CYP2C9) and clinical factors (eg, age, body surface area). This work fostered
www.WarfarinDosing.org, a National Institutes of Health (NIH)–supported site that
incorporates genetic and nongenetic factors to guide dosing.
Regarding resource-limited settings, Gary Maartens reminded participants that human
genetic diversity is greatest in Africa and that Africa also has the greatest HIV burden.
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Population genetic structure must be considered when assessing genetic tests. For example,
while HLA-B*5701 testing is routine in many countries, this variant is rare in native
Africans. It was once argued that CD4 cell testing was not feasible in Africa, but it is now
available based on its clinical importance and cost-effectiveness. Increased research in
Africa will likely identify novel and relevant genetic associations. Furthermore, knowledge
of population frequencies of relevant variants may inform policy.
The power of informatics to improve patient care was discussed by Dan Masys. He
recounted how, at one major US medical center, implementation of computerized provider
order entry (CPOE) markedly reduced medication prescribing errors. Human genomics is
the current archetype for health care complexity. Because handling such complex data
exceeds the ability of any practitioner, computerized clinical decision support and electronic
medical records will be critical. Genomics dramatically increases data complexity, but
failure to use such data will lead to suboptimal patient care. Broadly adopting electronic
medical records may help solve this problem.
STRATEGIES TO ADVANCE THE FIELD
Regarding clinical trials delivering genetic information, Jacques Fellay noted the importance
of large sample sizes, homogenous patient populations, and well-defined phenotypes for
genetic association analyses. He recounted the IDEAL study, a prospective trial of hepatitis
C virus (HCV) therapies. Most IDEAL participants consented for genetic research. By
GWAS, sustained virologic response rates were 80% and 30% among groups with favorable
and unfavorable IL28B alleles, respectively.23 Allele frequencies largely explain racial
disparities in HCV treatment response. This GWAS already shapes how HCV treatment and
drug development is considered, but it was only possible because consent for genomic
research was requested in IDEAL. He emphasized that every clinical trial should include
genetic consent and DNA collection for future analyses.
Challenges in prospectively testing genetic markers through clinical trials were described by
Elizabeth Phillips. The history of HLA-B*5701 screening for abacavir spanned 6 years from
discovery to clinical practice. The prospective, randomized PREDICT-1 study definitively
established the value of HLA-B*5701 testing among Caucasians and showed the importance
of an intermediate phenotype (abacavir skin patch testing) to define true immunologically
mediated abacavir hypersensitivity.6 The retrospective, case-control SHAPE study
replicated this association in patients of African descent.5 Many immune-mediated drug
reactions will involve HLA, but the combination of such a strong association for a problem
as prevalent as abacavir hypersensitivity is unlikely for most drugs. The abacavir story
exemplified the importance of various study designs, intermediate phenotypes, and
validation and ongoing quality assurance of laboratory technologies.
Prospective clinical trial designs relevant to pharmacogenomics were discussed by Heather
Ribaudo. Clinical trials provide more robust causal evidence than observational studies.
With targeted prospective designs, individuals of known genotype may be prospectively
studied specifically to collect information on phenotypes likely affected by genetics. With
restrictive/enrichment designs, genetic screening enriches the study population for
genotypes of interest and then randomizes participants to an intervention. These designs may
require relatively few participants to address targeted questions. She described benefits of a
large, phase 3 strategy design in which all potential drug recipients are randomized to
genetic screening or not (eg, PREDICT-16). Optimal design depends on the research
question. She noted benefits of precise, objective endpoints.
Regarding the cost-effectiveness of genetic testing, Kenneth Freedberg discussed
implications of cost-effectiveness analysis applied to clinical trials and strategies of care.
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Cost-effectiveness is a method of understanding the value of different interventions in HIV,
defining the incremental cost-effectiveness ratio in terms of dollars per year of life saved or
dollars per quality-adjusted life year saved. He described how higher CD4 counts correlate
with lower cost of care. In the United States, HLA-B*5701 testing has been shown to be
cost-effective by helping optimize the use of ART. Whether genomic testing will be cost-
effective in resource-limited settings will depend on the relative cost of the tests, the
prevalence of genomic variances, and cost and availability of different ART regimens.
Regarding diagnostic test development, Christos Petropoulos provided slides describing 2
routes to diagnostic test approval – the Hercep test (Dako North America, Inc., Carpinteria,
California, USA) and the Trofile assay (Monogram Biosciences, Inc., South San Francisco,
California, USA). Hercep identifies HER2-positive breast cancer, which can be treated with
trastuzumab. This standard of care test enables prescribing, with well-aligned positioning of
the diagnostic test by drug manufacturer and assay provider. The Trofile assay identifies
HIV-1 chemokine receptor tropism and informs prescribing of CCR5 inhibitors. This test is
also standard of care but is perceived as a barrier to prescribing. It is best if objectives of
pharmaceutical/biotechnology and diagnostic companies can be aligned. Opportunities
include reduced health care costs and expanded indications for targeted therapies.
Regarding genetics of complex traits, Teri Manolio described how GWAS has accelerated
progress in describing complex traits. She highlighted a Web page summarizing published
genome-wide associations (www.genome.gov/gwasstudies/). Lessons from GWAS include
surprising signals in unexpected genes, signals in gene “deserts” (regions devoid of protein-
coding genes), and individual genes associated with multiple disparate phenotypes. Small
genetic odds ratios may reflect contributions of environmental factors. Associations with
large effects will be hard to find if causative variants are rare.
RECOMMENDATIONS FROM WORKSHOP PARTICIPANTS
Working groups generated specific recommendations. Major recommendations are listed in
Table 2.
Recommendation 1: Every HIV-related clinical trial should offer participants the
opportunity to consent for future genetic analyses, with prolonged DNA storage and broad
scopes of analyses
At the time of clinical trial performance, all future genomic questions cannot be anticipated.
Every HIV-related clinical trial should therefore store DNA for future analysis. Consent
should encompass the broadest possible scope of genomic assays and clinical phenotypes. In
addition, DNA storage should be without time limit, because important genomic questions
may arise decades after trial completion.
Some attendees favored a federal mandate that all clinical trials bank DNA and that consent
for genetic analyses be required for participation in any trial. The prevailing sentiment
among attendees, however, was that these approaches would be prohibited by legal,
confidentiality, and other concerns. An alternative is to require that participants have the
opportunity to consent “yes” or “no” for future genetic analyses, without their response
affecting trial eligibility. The institutional review board (IRB) for at least one US academic
center requires that every protocol offers participants such an opportunity unless the
investigator justifies otherwise. Mandating such wording nationally, however, could
complicate trials enrollment and affect public sentiment about research. In some situations,
“opt-out” consenting may be feasible, in which genetic research is allowed unless the
participant proactively declines.24
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Ethics committees (ECs) and IRBs ultimately decide what is allowed. In the United States,
IRB decisions are independent and self-governing. Issues that may cause concern for IRBs
include indefinite duration of DNA storage and unlimited scope of analyses. At least some
non-US ECs may insist upon narrowly defined scopes of analyses and may be reluctant to
allow DNA or genetic data to leave their countries.
Recommendation 2: Create a Web-based catalogue of HIV clinical trials and cohorts
suitable for genetic analyses
A barrier to progress in HIV pharmacogenomics is lack of readily available information
regarding existing trial and cohort datasets with broad consent and available DNA. Many
genomic analyses occur only following chance interactions between genomic investigators
and individuals familiar with particular trials or cohorts. Cataloguing such information
would facilitate genetic discovery and replication. A Web-based listing of such studies,
including selected available phenotypes, need not be expensive and would include both
federally funded and non-federal studies. Individuals familiar with each study would
contribute a minimal amount of information. Non-US investigators should be involved from
the outset. To provide incentive for data uploads, one suggestion was to limit catalogue
queries to individuals who have uploaded data. Web sites already exist that compile
information about various aspects of clinical trials and/or pharmacogenomics (eg,
ClinicalTrials.gov, PharmGKB, HIV-Pharmacogenomics.org). One option would be to grow
the catalogue from an existing site.
Recommendation 3: Establish an international HIV pharmacogenomics consortium
Investigators worldwide have interests and expertise directly relevant to HIV
pharmacogenomics, but work in relative isolation. This is problematic, as many individual
datasets are inadequately powered to identify and/or replicate associations. In addition,
because genotype-phenotype associations may vary depending on genetic and environmental
factors, associations must be studied in different populations and contexts worldwide. The
number and diversity of potential pharmacogenomic questions require involvement of many
investigators. An international consortium of investigators could work together to identify
the most important HIV pharmacogenomic questions, develop phenotype precision and
consensus, combine datasets to address questions beyond the scope of individual groups or
datasets, and leverage resources to efficiently complete analyses. Such a consortium could
also enhance communication among HIV pharmacogenomic investigators.
Recommendation 4: Disseminate information regarding HIV pharmacogenomic research
widely and effectively
Pharmacogenomics investigators are understandably enthusiastic about the potential benefits
of their work, given the precedent of a genetic screening test that already improves HIV
drug safety and reduces cost (ie, HLA-B*5701 for abacavir hypersensitivity6). Other groups,
however, may not share this enthusiasm, perhaps due to concern that genetic information
may personally identify patients, that incorporating genomics into clinical care will increase
complexity or cost, or that benefits may not reach populations or countries in which
discoveries are made. To engage partners in this endeavor, information regarding benefits
and challenges of pharmacogenomic research must be effectively shared with persons living
with HIV, providers, researchers, policymakers, and the general public worldwide. The
consortium mentioned in Recommendation 3 could play a role in disseminating information.
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Recommendation 5: Support database, statistical, and computational genomics
infrastructures needed for successful HIV pharmacogenomics
Essential for progress in HIV pharmacogenomics research are robust clinical trial and cohort
datasets to merge with genomic data. An underappreciated aspect of this work is the need
for personnel with the skills and time for this task. Even with prospective trials and cohorts,
considerable data processing may be required to generate clean, well-documented datasets
for specific questions. Such work requires individuals who understand subtleties of study
design, performance, and data collection. For complex datasets with many possible
phenotypes of interest, judgment may be needed to prioritize analyses. There must be
sufficient support for all the personnel with complementary expertise needed for these
activities. Of note, the preparation of such datasets can be tedious and time-consuming and
may not be recognized for academic advancement.
ADDITIONAL POINTS OF DISCUSSION
Workshop participants emphasized a number of other points as follows. (1) To define
genotype-phenotype associations, various study designs should be pursued in parallel, not
sequentially (eg, observational and prospective studies, studies of clinical outcomes and
intermediate phenotypes, studies in different populations and contexts, etc). (2) When
observational evidence of genetic association is sufficiently strong, prospective clinical trials
to test genetic predictors may not be required. However, treatment guidelines are most
strongly affected by prospective trials, and information in different populations is required to
define generalizability. (3) Cost-effectiveness modeling plays an important role in assessing
genetic markers and the feasibility of application to clinical practice. (4) Both positive and
negative findings from genetic association studies should be presented. (5) Genetic studies
should consider nongenetic and ecological factors (eg, nutritional status, medication
adherence, concomitant medications, and concomitant illnesses). (6) The most relevant
phenotypes should be carefully chosen based on clinical impact. Considerations include
drugs that are widely used, and populations in which they are prescribed. (7) Identifying
genetic predictors of adverse events is most critical, but predictors of virologic response
would also be of considerable interest. (8) Pharmacogenomics studies should incorporate
pharmacokinetic analyses. Pharmaco-kinetic data enhance interpretation of genetic
association studies, and predictors of drug disposition could inform dosing schedules. (9)
Pharmacogenomics research benefits from an understanding of pharmacokinetic-
pharmacodynamic relationships. (10) As much information as possible should be gleaned
from extant data and specimens through association analyses, cost-effectiveness analyses,
and value-of-information analyses. (11) Merging data from various clinical trials and
cohorts would be facilitated if studies routinely and uniformly collected minimum sets of
key variables. (12) Results, implications, and generalizability of genetic association studies
may be context dependent. For example, some studies relevant to resource-limited countries
may not be relevant to other countries. (13) A potential application of pharmacogenomics in
resource-limited countries is to predict whether drugs are likely to be safe for their
population. For example, if a reliable genetic predictor of drug toxicity is identified, that
drug could be avoided in populations with high allelic frequencies of the predictor. (14)
Although most genetic markers may not reach clinical application, much may be learned
from genetic studies that elucidate underlying mechanisms of disease pathogenesis.
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Workshop Participants
The following individuals participated in this workshop: Rahel Abebe, MHS (HJF-DAIDS,
Bethesda, MD); Shashi Amur, PhD (FDA, Silver Spring, MD); Peter Anderson, PharmD
(University of Colorado Denver School of Pharmacy, Aurora, CO); Bradley Aouizerat, PhD
(University of California San Francisco School of Nursing, San Francisco, CA); Jing Bao,
MD, PhD (HJF-DAIDS, Bethesda, MD); George Bishopric, MD (Community
Representative, ACTG, Fort Lauderdale, FL); Sarita Boyd, PharmD (National Cancer
Institute, Bethesda, MD); Susan Brobst, PhD (NIAID, Bethesda, MD); Renee Browning,
MSN (HJF-NIAID, Bethesda, MD); David Burns, MD, MPH (NIAID, Bethesda, MD);
Stacy Carrington-Lawrence, PhD (NIH, Rockville, MD); Ling Chin, MD, MPH (NIAID,
Rockville, MD); Michael Court, BVSc, PhD (Tufts University School of Medicine, Boston,
MA); Steven Deeks, MD (University of California San Francisco, San Francisco, CA);
Marjorie Dehlinger, DNSc (NIH, Bethesda, MD); Vanessa Elharrar, MD, MPH (NIAID,
Bethesda, MD); Mariam Eljanne, PhD (NIAID, Bethesda, MD); Jacques Fellay, MD
(University of Lausanne, Lausanne, Switzerland); Kenneth A. Freedberg, MD, MSc
(Massachusetts General Hospital, Boston, MA); David Flockhart, MD, PhD (Indiana
University, Indianapolis, IN); Andrea Foulkes, ScD (University of Massachusetts, Amherst,
MA); Lawrence Fox, MD, PhD (NIAID, Bethesda, MD); Tia Frazier (NIAID, Bethesda,
MD); Brian Gage, MD (Washington University, St. Louis, MO); Ben Grady (Vanderbilt
University, Nashville, TN); Roy M. Gulick (Weill Medical College of Cornell University
New York, NY); Misrak Gezmu, PhD (NIH, Bethesda, MD); David W. Haas (Vanderbilt
University, Nashville, TN); Richard Haubrich, MD (University of California San Diego, San
Diego, CA); Todd Hulgan, MD, MPH (Vanderbilt University, Nashville, TN); Patrick Jean-
Philippe, MD (HJF-DAIDS, Bethesda, MD); Peter Kim, MD (NIAID, Bethesda, MD);
Daniel Kuritzkes, MD (Brigham and Women’s Hospital and Harvard Medical School,
Boston, MA); Saye Khoo, Professor (University of Liverpool, Liverpool, United Kingdom);
Karin Klingman, MD (NIAID, Bethesda, MD); Awewura Kwara, MD, MPH&TM (Brown
University, Providence, RI); Scott Letendre, MD (University of California San Diego, San
Diego, CA); Jonathan Li, MD (Brigham and Women’s Hospital and Harvard Medical
School, Boston, MA); Chenglong Liu (Georgetown University, Washington, DC); Gary
Maartens (University of Cape Town, Cape Town, South Africa), Teri A. Manolio, MD, PhD
(NIH, Bethesda, MD); Dan Masys (Vanderbilt University, Nashville, TN); Julia McEachern,
MHS, PA-C (Medco Health Solutions, Inc., Bethesda, MD); Paul McLaren, PhD (Brigham
and Women’s Hospital, Harvard Medical School, Boston, MA); Judi Miller, RN (NIAID,
Bethesda, MD); Jon Mirsalis, PhD (SRI International, Menlo Park, CA); Mostafa Nokta,
MD, PhD (National Cancer Institute, Bethesda, MD); Naomi O’Grady (Illumina, San Diego,
CA); Igho Ofotokun, MD, MSc (Emory University, Atlanta, GA); Andrew Owen, PhD
(University of Liverpool, Liverpool, United Kingdom); Christos Petropoulos, PhD
(Monogram Biosciences, South San Francisco, CA); Elizabeth Phillips, MD (Sir Charles
Gairdner Hospital, Royal Perth Hospital, Murdoch University & University of Western
Australia, Perth, Australia); Alice Pau, PharmD (NIAID, Bethesda, MD); Carla Pettinelli,
MD, PhD (NIAID, Bethesda, MD); Sonia Qasba, MD, MPH (Tuberculosis Control
Program, Montgomery County, MD); Heather J. Ribaudo, PhD (Statistical Data Analysis
Center, Harvard School of Public Health, Boston, MA); Marylyn D. Ritchie, PhD
(Vanderbilt University, Nashville, TN); Sarah Read, MD (NIAID, Bethesda, MD); Keisha
Robinson, MBA, MPM (Medco Health Solutions, Inc., Bethesda, MD); Jody Sachs, DPM
(National Center for Research Resources, Bethesda, MD); Bruce Schackman, PhD (Weill
Cornell Medical College, New York, NY); Helen Schiltz, PhD (NIAID, Bethesda, MD);
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Stuart Shapiro, MD, PhD (NIAID, Rockville, MD); Gerald Sharp, DrPH (NIAID, Bethesda,
MD); Phumla Sinxadi, MBChB (University of Cape Town, Cape Town, South Africa);
Nevilla K. Smith, RN (Henry M. Jackson Foundation, NIAID, Bethesda, MD); Wendy
Stevens, MD, MMed, FCPath (University of the Witwatersrand, Johannesburg, South
Africa); Philip E. Tarr, MD (University of Basel, Bruderholz, Switzerland); Amalio Telenti,
MD, PhD (University of Lausanne, Lausanne, Switzerland); Charles Venuto, PharmD
(University at Buffalo, University of Rochester, Rochester, NY); C. William Wester, MD
(Vanderbilt University, Nashville, TN); Sharon D. Williams (NIAID, Bethesda, MD);
Carolyn Williams, PhD, MPH (NIAID, Bethesda, MD); Chery Winkler, PhD (National
Cancer Institute, Frederick, MD); Hao Zhang, MD (NIAID, Bethesda, MD).
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Table 1
Well-established genetic associations for antiretroviral drugs
Drug Genotype Phenotype References
Abacavir HLA-B*5701 Hypersensitivity reaction 3–6
Atazanavir, indinavir UGT1A1*28 Hyperbilirubinemia 25–27
Efavirenz CYP2B6 516G→T, 983T→C, others Increased plasma concentration 8–13
Lopinavir SLCO1B1 521T→C Increased plasma concentration 18, 19, 28
Nelfinavir CYP2C19 681G→A Increased plasma concentration 10, 29
Nevirapine CYP2B6 516G→T Increased plasma concentration 9, 30–32
Nevirapine HLA-B*3505, -Cw*04, -DR*0101 Hypersensitivity reaction 14–17
Protease inhibitors APOC, others Dyslipidemia 21, 33, 34
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Table 2
Major recommendations from workshop participants
1. Every HIV-related clinical trial should offer participants the opportunity to consent for future genetic analyses, with prolonged DNA
storage and broad scopes of analyses.
2. Create a Web-based catalogue of HIV clinical trials and cohorts suitable for genetic analyses.
3. Establish an international HIV pharmacogenomics consortium.
4. Disseminate information regarding HIV pharmacogenomic research widely and effectively.
5. Support database, statistical, and computational genomics infrastructures needed for successful HIV pharmacogenomics.
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